Cited by Precisely engineering a dual-drug cooperative nanoassembly for proteasome inhibition-potentiated photodynamic therapy

Preparation and application of pH-responsive drug delivery systems DOI

Haitao Ding,

Ping Tan,

Shiqin Fu

et al.

Journal of Controlled Release, Journal Year: 2022, Volume and Issue: 348, P. 206 - 238

Published: June 8, 2022

Language: Английский

Citations

268

Carrier-free nanodrugs for safe and effective cancer treatment DOI

Sena Karaosmanoglu,

Mengjiao Zhou, Bingyang Shi

et al.

Journal of Controlled Release, Journal Year: 2020, Volume and Issue: 329, P. 805 - 832

Published: Oct. 9, 2020

Language: Английский

Citations

149

Ultrasound‐controlled drug release and drug activation for cancer therapy DOI

Li Tu,

Zhihuan Liao,

Zheng Luo

et al.

Exploration, Journal Year: 2021, Volume and Issue: 1(3)

Published: Dec. 1, 2021

Traditional chemotherapy suffers from severe toxicity and side effects that limit its maximum application in cancer therapy. To overcome this challenge, an ideal treatment strategy would be to selectively control the release or regulate activity of drugs minimize undesirable toxicity. Recently, ultrasound (US)-responsive drug delivery systems (DDSs) have attracted significant attention due non-invasiveness, high tissue penetration depth, spatiotemporal controllability US. Moreover, US-induced mechanical force has been proven a robust method site-selectively rearrange cleave bonds mechanochemistry. This review describes US-activated DDSs fundamental basics aims present comprehensive summary current understanding US-responsive for controlled activation. First, we summarize typical mechanisms Second, main factors affecting ultrasonic responsiveness carriers are outlined. Furthermore, representative examples US-controlled activation discussed, emphasizing their novelty design principles. Finally, challenges outlook on promising therapeutic discussed.

Language: Английский

Citations

132

Smart drug delivery systems for precise cancer therapy DOI

Xiaoyou Wang, Chong Li, Yiguang Wang

et al.

Acta Pharmaceutica Sinica B, Journal Year: 2022, Volume and Issue: 12(11), P. 4098 - 4121

Published: Aug. 22, 2022

Language: Английский

Citations

120

Stimulus-responsive self-assembled prodrugs in cancer therapy DOI

Xiao Dong, Rajeev Kungur Brahma, Chao Fang

et al.

Chemical Science, Journal Year: 2022, Volume and Issue: 13(15), P. 4239 - 4269

Published: Jan. 1, 2022

Small-molecule prodrugs have become the main toolbox to improve unfavorable physicochemical properties of potential therapeutic compounds in contemporary anti-cancer drug development. Many approved small-molecule prodrugs, however, still face key challenges their pharmacokinetic (PK) and pharmacodynamic (PD) properties, thus severely restricting further clinical applications. Self-assembled emerged as they could take advantage benefits both prodrug design nanomedicine, so maximize loading, reduce premature leakage, PK/PD parameters targeting ability. Notably, temporally spatially controlled release drugs at cancerous sites be achieved by encoding various activable linkers that are sensitive chemical or biological stimuli tumor microenvironment (TME). In this review, we comprehensively summarized recent progress made development single/multiple-stimulus-responsive self-assembled for mono- combinatorial therapy. A special focus was placed on conjugation strategies (polymer-drug conjugates, drug-drug

Language: Английский

Citations

Elaborately Engineering a Self‐Indicating Dual‐Drug Nanoassembly for Site‐Specific Photothermal‐Potentiated Thrombus Penetration and Thrombolysis DOI

Zhiqiang Zhao, Xuanbo Zhang, Hongyuan Zhang

et al.

Advanced Science, Journal Year: 2021, Volume and Issue: 9(4)

Published: Nov. 21, 2021

Abstract Thrombotic cardio‐cerebrovascular diseases seriously threaten human health. Currently, conventional thrombolytic treatments are challenged by the low utilization, inferior thrombus penetration, and high off‐target bleeding risks of most drugs, resulting in unsatisfactory treatment outcomes. Herein, it is proposed that these challenges can be overcome precisely integrating strategy with photothermal therapy. After co‐assembly engineering optimization, a fibrin‐targeting peptide‐decorated nanoassembly DiR (a probe) ticagrelor (TGL, an antiplatelet drug) prepared for thrombus‐homing delivery, abbreviated as FT‐DT NPs. The elaborately engineered shows multiple advantages, including simple preparation drug co‐loading capacity, synchronous delivery two drugs long systemic circulation, thrombus‐targeted accumulation self‐indicating function, well photothermal‐potentiated penetration thrombolysis therapeutic efficacy. As expected, NPs not only show bright fluorescence signals embolized vessels, but also perform photothermal/antiplatelet synergistic vivo. This study offers versatile co‐delivery nanoplatform imaging‐guided dual‐modality thrombolysis.

Language: Английский

Citations

Emerging nanomedicines of paclitaxel for cancer treatment DOI

Qin Chen, Shu Xu, Shuo Liu

et al.

Journal of Controlled Release, Journal Year: 2022, Volume and Issue: 342, P. 280 - 294

Published: Jan. 10, 2022

Language: Английский

Citations

Prodrug nanoassemblies bridged by Mono-/Di-/Tri-sulfide bonds: Exploration is for going further DOI

Yinxian Yang, Shiyi Zuo, Jingxuan Zhang

et al.

Nano Today, Journal Year: 2022, Volume and Issue: 44, P. 101480 - 101480

Published: April 8, 2022

Language: Английский

Citations

A prodrug hydrogel with tumor microenvironment and near-infrared light dual-responsive action for synergistic cancer immunotherapy DOI

Mengbin Ding,

Yongliang Fan,

Yicheng Lv

et al.

Acta Biomaterialia, Journal Year: 2022, Volume and Issue: 149, P. 334 - 346

Published: June 30, 2022

Language: Английский

Citations

Emerging nanotherapeutics for facilitating photodynamic therapy DOI

Shumeng Li,

Fujun Yang,

Yongdan Wang

et al.

Chemical Engineering Journal, Journal Year: 2022, Volume and Issue: 451, P. 138621 - 138621

Published: Aug. 12, 2022

Language: Английский

Citations